BioSpace News Archive

BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company has been awarded its Commercial and Government Entity (CAGE)

Collaboration will enhance precision and reproducible outcomes in total knee replacements

Exagen Inc., an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced a collaboration with Hospital for Special Surgery in New York City.

Voyager Therapeutics, Inc., a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, announced the termination of its tau and alpha-synuclein vectorized antibody collaborations with AbbVie.

Successfully completed Phase 1b trial of AVB-500 in Platinum Resistant Ovarian Cancer with encouraging clinical data showing 60% ORR in the subpopulation that has not previously been treated with bevacizumab

Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, announced that it will host a conference call on Monday, August 10, 2020, at 4:30 p.m. ET to discuss its financial results for the three months ended June 30, 2020, and recent operational highlights.

Karyopharm Therapeutics Inc., an innovation-driven pharmaceutical company, announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 27,300 shares of Karyopharm’s common stock to three newly-hired employees, with a grant date of July 31, 2020.

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Monday, August 10, 2020

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Company will release its second quarter 2020 financial results before the open of the U.S. financial markets on Monday, August 10, 2020.

Ra Medical Systems, Inc. announced that it has closed the previously announced public offering of an aggregate of 34,285,714 shares of common stock, together with accompanying warrants to purchase up to an aggregate of 34,285,714 shares of common stock, at a public offering price of $0.35 per share and accompanying warrant.